Solid Biosciences Inc.
SLDB
$6.83
-$0.01-0.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 63.80% | 25.95% | -- | -- | -- |
| Gross Profit | -63.80% | -25.95% | -- | -- | -- |
| SG&A Expenses | 14.38% | 33.97% | 22.50% | 16.80% | 7.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.10% | 79.19% | 52.21% | 3.28% | -16.13% |
| Operating Income | -49.10% | -79.19% | -52.21% | -3.28% | 16.13% |
| Income Before Tax | -61.63% | -109.47% | -55.98% | -1.80% | 19.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.63% | -109.47% | -55.98% | -1.80% | 19.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.63% | -109.47% | -55.98% | -1.80% | 19.18% |
| EBIT | -49.10% | -79.19% | -52.21% | -3.28% | 16.13% |
| EBITDA | -49.41% | -78.70% | -54.39% | -2.91% | 15.37% |
| EPS Basic | 7.03% | 0.76% | 24.51% | 51.10% | 58.55% |
| Normalized Basic EPS | 7.03% | 0.75% | 24.51% | 51.22% | 58.55% |
| EPS Diluted | 7.03% | 0.76% | 24.51% | 51.10% | 58.64% |
| Normalized Diluted EPS | 7.03% | 0.75% | 24.51% | 51.22% | 58.55% |
| Average Basic Shares Outstanding | 73.87% | 111.06% | 106.60% | 108.17% | 94.99% |
| Average Diluted Shares Outstanding | 73.87% | 111.06% | 106.60% | 108.17% | 94.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |